We are live on ! Find out more
TBPH icon

Theravance Biopharma
TBPH

96 hedge funds and large institutions have $1.22B invested in Theravance Biopharma in 2018 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 39 increasing their positions, 22 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

77% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 22

21% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 14

3% more funds holding

Funds holding: 93 → 96 (+3)

0.04% more ownership

Funds ownership: 86.03% → 86.07% (+0.04%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

21% less capital invested

Capital invested by funds: $1.55B → $1.22B (-$328M)

Holders
96
Holders Change
+3
Holders Change %
+3.23%
% of All Funds
2.14%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
17
Increased
39
Reduced
22
Closed
14
Calls
$245K
Puts
–
Net Calls
+$245K
Net Calls Change
-$457K

Top Buyers

Rank Fund Capital Flow
1
WIM
Woodford Investment Management
United Kingdom
+$16.8M
2
Morgan Stanley
Morgan Stanley
New York
+$13.7M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$8.32M
4
JP Morgan Chase
JP Morgan Chase
New York
+$3.44M
5
First Trust Advisors
First Trust Advisors
Illinois
+$2.37M

Top Sellers

Rank Fund Capital Flow
1
CCM
Consonance Capital Management
New York
-$23.9M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$9.8M
3
CAM
Cormorant Asset Management
Massachusetts
-$5.81M
4
Millennium Management
Millennium Management
New York
-$4.3M
5
Deutsche Bank
Deutsche Bank
Germany
-$3.79M
Name Holding Trade Value Shares
Change 		Change in
Stake
RA
26
Royce & Associates
New York
$2.39M – – –
First Trust Advisors
27
First Trust Advisors
Illinois
$2.24M +$2.37M +87,633 New
Swiss National Bank
28
Swiss National Bank
Switzerland
$2M +$75.6K +2,800 +4%
D.E. Shaw & Co
29
D.E. Shaw & Co
New York
$1.92M +$645K +23,885 +47%
California State Teachers Retirement System (CalSTRS)
30
California State Teachers Retirement System (CalSTRS)
California
$1.73M +$59.2K +2,194 +3%
AllianceBernstein
31
AllianceBernstein
Tennessee
$1.61M -$18.9K -700 -1%
California Public Employees Retirement System
32
California Public Employees Retirement System
California
$1.45M -$148K -5,500 -9%
RhumbLine Advisers
33
RhumbLine Advisers
Massachusetts
$1.43M +$506K +18,752 +51%
CEP
34
Chicago Equity Partners
Illinois
$1.38M +$1.45M +53,860 New
Deutsche Bank
35
Deutsche Bank
Germany
$1.34M -$3.79M -140,498 -73%
Federated Hermes
36
Federated Hermes
Pennsylvania
$1.18M +$1.24M +46,008 New
State of Wisconsin Investment Board
37
State of Wisconsin Investment Board
Wisconsin
$1.13M +$13.5K +500 +1%
New York State Common Retirement Fund
38
New York State Common Retirement Fund
New York
$1.08M -$113K -4,200 -9%
CS
39
Credit Suisse
Switzerland
$997K +$146K +5,398 +16%
II
40
Ibex Investors
Colorado
$916K -$278K -10,297 -22%
Citadel Advisors
41
Citadel Advisors
Florida
$775K +$249K +9,214 +44%
UBS Group
42
UBS Group
Switzerland
$754K +$630K +23,324 +378%
NSEDCP
43
NJ State Employees Deferred Compensation Plan
New Jersey
$746K -$135K -5,000 -15%
State Board of Administration of Florida Retirement System
44
State Board of Administration of Florida Retirement System
Florida
$731K – – –
AIG
45
American International Group
New York
$729K +$1.86K +69 +0.2%
Manulife (Manufacturers Life Insurance)
46
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$700K -$7.13K -264 -1%
Invesco
47
Invesco
Georgia
$639K -$25K -926 -4%
ProShare Advisors
48
ProShare Advisors
Maryland
$597K -$118K -4,369 -16%
VEA
49
Virtus ETF Advisers
New York
$574K -$264K -9,783 -30%
UBS AM
50
UBS AM
Illinois
$521K +$83.7K +3,100 +18%
1
2
3 4 5

TBPH Hedge Fund Activity: Q4 2018 in Review

96 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q4 2018, worth a combined $1.22B — down 21% from $1.55B a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new TBPH positions and 14 closed out — a net gain of 3 holders — while 39 added to existing stakes and 22 trimmed.

The largest buyer was Woodford Investment Management, adding an estimated $16.8M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $23.9M sold.

  • 96 institutional investors held Theravance Biopharma (TBPH) as of Q4 2018, up from 93 in Q3 2018.
  • Funds reported $1.22B of Theravance Biopharma stock for Q4 2018, down 21% quarter-over-quarter.
  • 17 funds opened new Theravance Biopharma positions in Q4 2018 and 14 closed out, a net change of +3 holders.
  • The largest Theravance Biopharma buyer in Q4 2018 was Woodford Investment Management, an estimated $16.8M added.
  • The largest Theravance Biopharma seller in Q4 2018 was Consonance Capital Management, an estimated $23.9M sold.

Based on aggregated 13F filings for Q4 2018.